**Table S43. Complex human traits and diseases associated with variants within testis enhancers and those in LD with variants that reside in testis enhancers that exhibit significant evidence of recent selection**

|  |  |  |  |
| --- | --- | --- | --- |
| **Enhancer ID** | **rsID** | **Traits** | **Metrics** |
| chr1:144533627-144534178 | rs140656307 | Itch intensity from mosquito bite  adjusted by bite size | Tajima’s *D*, *F*ST |
| chr1:149984633-149984917 | rs1960306 | Peripheral arterial disease  (traffic-related air pollution interaction) | *nS*L (AFR) |
| chr1:196778400-196778793 | rs480745 | Spontaneous preterm birth (preterm birth) | *nS*L (EAS) |
| chr1:205283024-205283394 | rs190567396 | Hepatitis A | Tajima’s *D* |
| chr1:229341143-229341392 | rs648425 | Systolic blood pressure  (alcohol consumption interaction) | *nS*L(AFR), *F*ST |
| chr1:26946837-26947249 | rs192013290 | Late-onset Alzheimer's disease | Tajima’s *D* |
| chr2:129901785-129902172 | rs141034416 | Post bronchodilator FEV1/FVC ratio | *nS*L (AFR) |
| chr2:8190570-8190676 | rs1012307 | Asthma (sex interaction) | H12 |
| chr3:139082145-139082521 | rs13317079 | Obesity-related traits | *F*ST |
| chr4:140003738-140004448 | rs77156671 | Diisocyanate-induced asthma | Tajima’s *D* |
| chr4:140656102-140656508 | rs188426604 | Bacterial meningitis | Tajima’s *D* |
| chr4:190285262-190285611 | rs10034465 | Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes | *nS*L (AFR, EUR, EAS) |
| chr5:125730040-125730374 | rs4340940 | Ankle injury | Tajima’s *D* |
| chr6:132468651-132469082 | rs148347825 | Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes | *F*ST |
| chr6:157007979-157008724 | rs149967400 | Cold sores | Tajima’s *D* |
| chr6:157007979-157008724 | rs188657011 | Post bronchodilator FEV1/FVC ratio | Tajima’s *D* |
| chr6:157007979-157008724 | rs75556600 | Post bronchodilator FEV1 | Tajima’s *D* |
| chr6:157342507-157343524 | rs34704616 | Cognitive performance | Tajima’s *D* |
| chr6:157342507-157343524 | rs557966248 | Reticulocyte fraction of red cells, Reticulocyte count, High light scatter reticulocyte count, High light scatter reticulocyte percentage of  red cells | Tajima’s *D* |
| chr6:157342507-157343524 | rs6909762 | Peripheral arterial disease  (traffic-related air pollution interaction) | Tajima’s *D* |
| chr6:157342507-157343524 | rs736088 | Peripheral arterial disease  (traffic-related air pollution interaction) | Tajima’s *D* |
| chr6:30069810-30070038 | rs1111180 | Eosinophil percentage of granulocytes,  Eosinophil percentage of white cells | *nS*L (EUR) |
| chr6:30923441-30923743 | rs17189763 | Conotruncal heart defects (maternal effects) | *nS*L (EUR) |
| chr6:30923441-30923743 | rs184898731 | Mosquito bite size | *nS*L (EUR) |
| chr6:31352932-31353063 | rs13437082 | Height, Cerebrospinal fluid biomarker levels | *nS*L (AFR, EUR, EAS) |
| chr6:31352932-31353063 | rs13437088 | Psoriasis | *nS*L (AFR, EUR, EAS) |
| chr6:31352932-31353063 | rs16899524 | Beta-2 microglubulin plasma levels | *nS*L (AFR, EUR, EAS) |
| chr6:31352932-31353063 | rs2596542 | Hepatocellular carcinoma | *nS*L (AFR, EUR, EAS) |
| chr6:31352932-31353063 | rs7751505 | Pubertal anthropometrics | *nS*L (AFR, EUR, EAS) |
| chr6:35569141-35569999 | rs6457821 | Height | Tajima’s *D* |
| chr7:157956905-157957265 | rs77255239 | Low white blood cell count  (conditioned on rs2814778) | *nS*L (AFR, EUR, EAS) |
| chr7:157956905-157957265 | rs77998448 | Low white blood cell count  (conditioned on rs2814778) | *nS*L (AFR, EUR, EAS) |
| chr7:157956905-157957265 | rs80278508 | Stromal-cell-derived factor 1 alpha levels | *nS*L (AFR, EUR, EAS) |
| chr7:23513815-23514383 | rs7807274 | Asthma (childhood onset) | Tajima’s *D* |
| chr7:39332685-39332952 | rs146622168 | Post bronchodilator FEV1 | *nS*L (AFR) |
| chr11:62319122-62319673 | rs11213935 | Obesity-related traits | Tajima’s *D* |
| chr11:62319122-62319673 | rs115514216 | Alzheimer disease and age of onset | Tajima’s *D* |
| chr11:98114746-98115057 | rs200072888 | Stem cell growth factor beta levels | Tajima’s *D* |
| chr11:98114746-98115057 | rs3842770 | Type 2 diabetes | Tajima’s *D* |
| chr12:122124782-122125118 | rs143838781 | Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes | Tajima’s *D* |
| chr12:122124782-122125118 | rs28667979 | Peripheral arterial disease  (traffic-related air pollution interaction) | Tajima’s *D* |
| chr12:133021534-133022956 | rs182599555 | Rubella | *nS*L (AFR, EUR, EAS) |
| chr14:69618210-69618757 | rs77327054 | Mean platelet volume | Tajima’s *D* |
| chr14:69618210-69618757 | rs79936776 | Platelet count | Tajima’s *D* |
| chr16:52643083-52643359 | rs75728418 | 3-hydroxypropylmercapturic acid levels in smokers | Tajima’s *D* |
| chr16:74701397-74701877 | rs16948255 | HIV-1 control | Tajima’s *D* |
| chr16:90143699-90144065 | rs143661751 | Post bronchodilator FEV1/FVC ratio | *F*ST |
| chr17:38477236-38480096 | rs7210100 | Prostate cancer | Tajima’s *D* |
| chr17:38477236-38480096 | rs8073525 | Peripheral arterial disease  (traffic-related air\_ pollution interaction) | Tajima’s *D* |
| chr17:76412850-76413399 | rs73373322 | Iron status biomarkers (iron levels),  Iron status biomarkers (transferrin saturation) | Tajima’s *D* |
| chr20:26116339-26116766 | rs187497509 | Post bronchodilator FEV1/FVC ratio | Tajima’s *D* |
| chr22:24255997-24256450 | rs183544847 | Post bronchodilator FEV1/FVC ratio | Tajima’s *D* |